GlassScriptPhysician profile
Christina M Ring
NPI 1780110023
$3,616.52
in general payments reported to CMS, 2019-2025
20 companies · $873 in 2025
The $873 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $568 · 2020: $39.18 · 2021: $89.55 · 2022: $887 · 2023: $1,021 · 2024: $139 · 2025: $873.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,905 · Education: $99.00 · Travel and Lodging: $30.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,904.68 |
| Education | $99.00 |
| Travel and Lodging | $30.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,299.71 | 2019-2025 | Skyrizi, Botox, Rinvoq |
| Genzyme Corporation | $374.28 | 2019-2025 | |
| Janssen Biotech, INC. | $320.85 | 2022-2023 | Tremfya |
| Pfizer INC. | $277.59 | 2022-2025 | |
| Amgen INC. | $205.06 | 2022-2023 | Otezla |
| Allergan, INC. | $184.44 | 2019-2022 | |
| Helsinn Therapeutics (U.S.), INC. | $156.89 | 2019-2023 | Valchlor |
| Sun Pharmaceutical Industries INC. | $149.86 | 2022-2023 | Winlevi, Ilumya |
| Novartis Pharmaceuticals Corporation | $102.06 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $87.03 | 2020-2025 | Dupixent |
| Almirall LLC | $70.18 | 2023 | Klisyri |
| Sanofi-Aventis U.S. LLC | $69.99 | 2021 | |
| Ucb, INC. | $68.60 | 2023 | Cimzia |
| Biofrontera INC. | $62.34 | 2022 | |
| Solta Medical, A Division of Bausch Health US, LLC | $46.53 | 2025 | Fraxel |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $43.36 | 2022-2023 | Taltz, Olumiant |
| Strata Skin Sciences, INC. | $32.72 | 2022 | |
| Revance Therapeutics, INC. | $24.38 | 2025 | Daxxify |
| Incyte Corporation | $22.05 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $18.60 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christina Ring listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.